Free Trial

Quick list of bargain stocks to end the year

stocks to buy

Key Points

  • The FED has pivoted into a dovish stance, creating a significant reason to turn bullish on stocks, especially those that are cheaper than they should be.
  • Three stocks will jump out to fit the description: the fallen soldiers that could inevitably catch up to indices.
  • Analysts see everything right with them, building the upside case.
  • 5 stocks we like better than Pfizer.

Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward equity markets. Now, the FED has hinted at the possibility of cutting interest rates in 2024; what does that mean for markets?

Lowering rates means that money becomes cheaper, and consumers treat it as such. This also means more consumer spending and financing activity from businesses, as they need to expand to meet the coming demand. Enough cliff notes; knowing what you know now, what are some cheap stocks that are set to take off in this new wave?

Judging by their current valuations and other 'big picture' dynamics, these could be the easiest picks you come across for an end-of-the-year portfolio update. You'll discover why Alibaba Group NYSE: BABA, Walgreens Boots Alliance NASDAQ: WBA, and Pfizer NYSE: PFE all deserve a second look for a potential watchlist.

Make it make sense

Within healthcare stocks, Pfizer finds itself in a very peculiar situation. The sector trades at an average of 89.3% of its 52-week high. In comparison, Pfizer stock falls way behind at 49.0%, making it the worst performer in the sector during that period.

Alibaba could be the most misunderstood name on this list, as virtually every investor believes that Chinese stocks are a minefield, one wrong step, and you're wiped out. However, considering the company's financials, you'll find that 1+1 does not equal two.

Since its IPO (initial public offering) in 2014, Alibaba has grown its revenues by ten times. Management is buying back up to 10% of the company's size in stock. Yet, today's stock price is lower than when the company was introduced to the New York Stock Exchange.

Walgreens is one of those 'eight to eighty' stocks that would shock just about anyone if the brand name ceases to exist in the next decade; it is an American staple! Its clientele is made up of kids eight years old looking for candy and snacks to eighty-year-old citizens picking up medicine or other conveniences.

A thing like that, and there really is no other competitor to this business other than CVS Health NYSE: CVS in that space. Considering that Walgreens trades 34.8% lower than CVS (on a price-to-earnings basis), why would Walgreens not be the clear value pick?

Now these are just surface-level features; it's time to dig a little deeper to understand if markets are in line with the potential in these businesses.

Just in: analysts agree

Typically, analysts don't stick their necks - and reputations - out on a falling stock or ones considered cheap by the marketplace. The saying 'it must be cheap for a reason' haunts them into undercovering such names, and most of the time, for good reason.

This time, you'd be surprised at how optimistic they have turned toward these stocks. Expecting a 101.3% jump in earnings per share, Pfizer analysts are placing the weight of their conviction into this name to carry the industry higher.

From these projections, a price target of $40.3 a share roots out, implying the stock needs to jump by 54.4% from today's prices to meet it. Is it cheap enough now?

Walgreens is pretty close behind, with analysts expecting EPS to advance by 9.3% in the next twelve months, which is strong for the space. Being a leader next to CVS, a price target of $29.4 a share seems more than justified, bringing you a 16.8% upside in America's convenience darling.

Now, jumping across the world to Alibaba, here is where you would expect analysts to shy away from being too optimistic, right? Well, the fearless Wall Streeters at J.P. Morgan Chase & Co. NYSE: JPM see a price target of $125.0 a share, which is 61.5% higher than today's price!

If you follow price action religiously, you will find that all three stocks are trading below 80.0% of their 52-week highs, fitting Wall Street's definition of a bear market (which starts at a 20% decline of highs).

Now that stock markets are pushing for new highs on the FED news, Jessee Livermore's saying, "The soldiers always follow the generals," may come true. These fallen soldiers could aggressively catch up to the general indices.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Gabriel Osorio-Mazilli
About The Author

Gabriel Osorio-Mazilli

Contributing Author

Value Stocks, Asian Markets, Macro Economics

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Alibaba Group (BABA)
4.8871 of 5 stars
$85.52+0.4%1.15%17.35Moderate Buy$114.07
CVS Group (CVSG)
1.7906 of 5 stars
GBX 826+0.7%0.97%2,294.44BuyGBX 2,370
Walgreens Boots Alliance (WBA)
4.198 of 5 stars
$9.19-1.2%10.88%-0.92Reduce$12.58
Pfizer (PFE)
4.9757 of 5 stars
$26.74+0.1%6.43%36.14Hold$32.14
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

Why Energy Stocks Are Poised for Explosive Growth in 2025
From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines